nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCC4—Sorafenib—thyroid cancer	0.0867	0.763	CbGbCtD
Dipyridamole—PDE8B—larynx—thyroid cancer	0.0279	0.12	CbGeAlD
Dipyridamole—ABCB1—Sorafenib—thyroid cancer	0.0168	0.148	CbGbCtD
Dipyridamole—ABCB1—Doxorubicin—thyroid cancer	0.0102	0.0897	CbGbCtD
Dipyridamole—PDE6A—head—thyroid cancer	0.009	0.0388	CbGeAlD
Dipyridamole—PDE6C—head—thyroid cancer	0.00853	0.0368	CbGeAlD
Dipyridamole—PDE8B—neck—thyroid cancer	0.00739	0.0319	CbGeAlD
Dipyridamole—PDE1C—thyroid gland—thyroid cancer	0.00712	0.0307	CbGeAlD
Dipyridamole—PRUNE—thyroid gland—thyroid cancer	0.00642	0.0277	CbGeAlD
Dipyridamole—PDE1C—head—thyroid cancer	0.00631	0.0272	CbGeAlD
Dipyridamole—PDE6D—thyroid gland—thyroid cancer	0.0062	0.0267	CbGeAlD
Dipyridamole—PDE6B—thyroid gland—thyroid cancer	0.0061	0.0263	CbGeAlD
Dipyridamole—PDE11A—thyroid gland—thyroid cancer	0.00567	0.0244	CbGeAlD
Dipyridamole—PDE6B—head—thyroid cancer	0.00541	0.0233	CbGeAlD
Dipyridamole—PDE6H—head—thyroid cancer	0.00503	0.0217	CbGeAlD
Dipyridamole—PDE6G—head—thyroid cancer	0.00484	0.0209	CbGeAlD
Dipyridamole—PDE2A—trachea—thyroid cancer	0.00466	0.0201	CbGeAlD
Dipyridamole—PDE7A—head—thyroid cancer	0.00448	0.0193	CbGeAlD
Dipyridamole—PDE1C—lymph node—thyroid cancer	0.00442	0.0191	CbGeAlD
Dipyridamole—PDE7B—thyroid gland—thyroid cancer	0.00442	0.019	CbGeAlD
Dipyridamole—PDE8A—trachea—thyroid cancer	0.004	0.0172	CbGeAlD
Dipyridamole—PRUNE—lymph node—thyroid cancer	0.00399	0.0172	CbGeAlD
Dipyridamole—PDE7B—head—thyroid cancer	0.00392	0.0169	CbGeAlD
Dipyridamole—PDE6D—lymph node—thyroid cancer	0.00385	0.0166	CbGeAlD
Dipyridamole—PDE2A—thyroid gland—thyroid cancer	0.00369	0.0159	CbGeAlD
Dipyridamole—PDE10A—thyroid gland—thyroid cancer	0.00369	0.0159	CbGeAlD
Dipyridamole—PDE1B—thyroid gland—thyroid cancer	0.00365	0.0158	CbGeAlD
Dipyridamole—PDE8B—thyroid gland—thyroid cancer	0.00352	0.0152	CbGeAlD
Dipyridamole—PDE6G—lymph node—thyroid cancer	0.00339	0.0146	CbGeAlD
Dipyridamole—PDE2A—head—thyroid cancer	0.00327	0.0141	CbGeAlD
Dipyridamole—PDE10A—head—thyroid cancer	0.00327	0.0141	CbGeAlD
Dipyridamole—PDE1B—head—thyroid cancer	0.00324	0.014	CbGeAlD
Dipyridamole—PDE8A—thyroid gland—thyroid cancer	0.00316	0.0136	CbGeAlD
Dipyridamole—PDE8B—head—thyroid cancer	0.00312	0.0135	CbGeAlD
Dipyridamole—PDE1A—thyroid gland—thyroid cancer	0.00306	0.0132	CbGeAlD
Dipyridamole—PDE7B—lymph node—thyroid cancer	0.00274	0.0118	CbGeAlD
Dipyridamole—PDE1A—head—thyroid cancer	0.00272	0.0117	CbGeAlD
Dipyridamole—ADA—thyroid gland—thyroid cancer	0.0026	0.0112	CbGeAlD
Dipyridamole—PDE4A—thyroid gland—thyroid cancer	0.00254	0.0109	CbGeAlD
Dipyridamole—ADA—head—thyroid cancer	0.00231	0.00996	CbGeAlD
Dipyridamole—PDE10A—lymph node—thyroid cancer	0.00229	0.00988	CbGeAlD
Dipyridamole—PDE2A—lymph node—thyroid cancer	0.00229	0.00988	CbGeAlD
Dipyridamole—SLC29A1—trachea—thyroid cancer	0.00229	0.00987	CbGeAlD
Dipyridamole—PDE1B—lymph node—thyroid cancer	0.00227	0.00979	CbGeAlD
Dipyridamole—PDE8B—lymph node—thyroid cancer	0.00218	0.00942	CbGeAlD
Dipyridamole—PDE5A—thyroid gland—thyroid cancer	0.00216	0.0093	CbGeAlD
Dipyridamole—PDE3B—lymph node—thyroid cancer	0.00213	0.0092	CbGeAlD
Dipyridamole—PDE3A—thyroid gland—thyroid cancer	0.0021	0.00905	CbGeAlD
Dipyridamole—ABCC5—thyroid gland—thyroid cancer	0.00197	0.00851	CbGeAlD
Dipyridamole—PDE8A—lymph node—thyroid cancer	0.00196	0.00847	CbGeAlD
Dipyridamole—PDE5A—head—thyroid cancer	0.00191	0.00825	CbGeAlD
Dipyridamole—PDE1A—lymph node—thyroid cancer	0.0019	0.0082	CbGeAlD
Dipyridamole—SLC29A1—thyroid gland—thyroid cancer	0.00181	0.00781	CbGeAlD
Dipyridamole—ADA—lymph node—thyroid cancer	0.00162	0.00697	CbGeAlD
Dipyridamole—SLC29A1—head—thyroid cancer	0.00161	0.00693	CbGeAlD
Dipyridamole—PDE4A—lymph node—thyroid cancer	0.00158	0.0068	CbGeAlD
Dipyridamole—ABCC4—thyroid gland—thyroid cancer	0.00137	0.0059	CbGeAlD
Dipyridamole—PDE5A—lymph node—thyroid cancer	0.00134	0.00578	CbGeAlD
Dipyridamole—PDE3A—lymph node—thyroid cancer	0.0013	0.00562	CbGeAlD
Dipyridamole—ABCC5—lymph node—thyroid cancer	0.00123	0.00528	CbGeAlD
Dipyridamole—ABCC4—head—thyroid cancer	0.00121	0.00523	CbGeAlD
Dipyridamole—SLC29A1—lymph node—thyroid cancer	0.00113	0.00485	CbGeAlD
Dipyridamole—Fatigue—Vandetanib—thyroid cancer	0.00112	0.00432	CcSEcCtD
Dipyridamole—Angiopathy—Sorafenib—thyroid cancer	0.00112	0.00432	CcSEcCtD
Dipyridamole—Immune system disorder—Sorafenib—thyroid cancer	0.00111	0.0043	CcSEcCtD
Dipyridamole—Rigors—Epirubicin—thyroid cancer	0.00111	0.00429	CcSEcCtD
Dipyridamole—Injection site pain—Epirubicin—thyroid cancer	0.00111	0.00429	CcSEcCtD
Dipyridamole—Mediastinal disorder—Sorafenib—thyroid cancer	0.00111	0.00429	CcSEcCtD
Dipyridamole—Pain—Vandetanib—thyroid cancer	0.00111	0.00429	CcSEcCtD
Dipyridamole—Dysphonia—Epirubicin—thyroid cancer	0.0011	0.00426	CcSEcCtD
Dipyridamole—Arrhythmia—Sorafenib—thyroid cancer	0.0011	0.00425	CcSEcCtD
Dipyridamole—Alopecia—Sorafenib—thyroid cancer	0.00109	0.00421	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00106	0.0041	CcSEcCtD
Dipyridamole—Dysgeusia—Sorafenib—thyroid cancer	0.00105	0.00406	CcSEcCtD
Dipyridamole—Breast pain—Epirubicin—thyroid cancer	0.00104	0.00402	CcSEcCtD
Dipyridamole—Muscle spasms—Sorafenib—thyroid cancer	0.00103	0.00399	CcSEcCtD
Dipyridamole—Injection site pain—Doxorubicin—thyroid cancer	0.00103	0.00397	CcSEcCtD
Dipyridamole—Rigors—Doxorubicin—thyroid cancer	0.00103	0.00397	CcSEcCtD
Dipyridamole—Abdominal pain—Vandetanib—thyroid cancer	0.00102	0.00396	CcSEcCtD
Dipyridamole—Dysphonia—Doxorubicin—thyroid cancer	0.00102	0.00394	CcSEcCtD
Dipyridamole—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.001	0.00388	CcSEcCtD
Dipyridamole—Bone disorder—Epirubicin—thyroid cancer	0.001	0.00388	CcSEcCtD
Dipyridamole—Anaemia—Sorafenib—thyroid cancer	0.000989	0.00383	CcSEcCtD
Dipyridamole—Angioedema—Sorafenib—thyroid cancer	0.000978	0.00379	CcSEcCtD
Dipyridamole—Syncope—Sorafenib—thyroid cancer	0.00096	0.00372	CcSEcCtD
Dipyridamole—Breast pain—Doxorubicin—thyroid cancer	0.00096	0.00372	CcSEcCtD
Dipyridamole—Loss of consciousness—Sorafenib—thyroid cancer	0.000941	0.00364	CcSEcCtD
Dipyridamole—Cough—Sorafenib—thyroid cancer	0.000934	0.00362	CcSEcCtD
Dipyridamole—Atrioventricular block—Epirubicin—thyroid cancer	0.000933	0.00361	CcSEcCtD
Dipyridamole—Asthenia—Vandetanib—thyroid cancer	0.000929	0.0036	CcSEcCtD
Dipyridamole—Bone disorder—Doxorubicin—thyroid cancer	0.000927	0.00359	CcSEcCtD
Dipyridamole—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.000927	0.00359	CcSEcCtD
Dipyridamole—Hypertension—Sorafenib—thyroid cancer	0.000924	0.00358	CcSEcCtD
Dipyridamole—Coordination abnormal—Epirubicin—thyroid cancer	0.000921	0.00357	CcSEcCtD
Dipyridamole—Pruritus—Vandetanib—thyroid cancer	0.000916	0.00355	CcSEcCtD
Dipyridamole—Musculoskeletal pain—Epirubicin—thyroid cancer	0.000916	0.00355	CcSEcCtD
Dipyridamole—Myalgia—Sorafenib—thyroid cancer	0.000911	0.00353	CcSEcCtD
Dipyridamole—Arthralgia—Sorafenib—thyroid cancer	0.000911	0.00353	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000905	0.0035	CcSEcCtD
Dipyridamole—Ventricular tachycardia—Epirubicin—thyroid cancer	0.000905	0.0035	CcSEcCtD
Dipyridamole—Injection site reaction—Epirubicin—thyroid cancer	0.0009	0.00348	CcSEcCtD
Dipyridamole—Dry mouth—Sorafenib—thyroid cancer	0.000891	0.00345	CcSEcCtD
Dipyridamole—Eructation—Epirubicin—thyroid cancer	0.000889	0.00344	CcSEcCtD
Dipyridamole—Diarrhoea—Vandetanib—thyroid cancer	0.000886	0.00343	CcSEcCtD
Dipyridamole—Anaphylactic shock—Sorafenib—thyroid cancer	0.000874	0.00338	CcSEcCtD
Dipyridamole—Atrioventricular block—Doxorubicin—thyroid cancer	0.000863	0.00334	CcSEcCtD
Dipyridamole—Shock—Sorafenib—thyroid cancer	0.000859	0.00333	CcSEcCtD
Dipyridamole—Nervous system disorder—Sorafenib—thyroid cancer	0.000857	0.00332	CcSEcCtD
Dipyridamole—Dizziness—Vandetanib—thyroid cancer	0.000856	0.00332	CcSEcCtD
Dipyridamole—Thrombocytopenia—Sorafenib—thyroid cancer	0.000855	0.00331	CcSEcCtD
Dipyridamole—Coordination abnormal—Doxorubicin—thyroid cancer	0.000853	0.0033	CcSEcCtD
Dipyridamole—ABCC4—lymph node—thyroid cancer	0.000849	0.00366	CbGeAlD
Dipyridamole—Skin disorder—Sorafenib—thyroid cancer	0.000848	0.00329	CcSEcCtD
Dipyridamole—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.000847	0.00328	CcSEcCtD
Dipyridamole—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.000837	0.00324	CcSEcCtD
Dipyridamole—Injection site reaction—Doxorubicin—thyroid cancer	0.000832	0.00322	CcSEcCtD
Dipyridamole—Vomiting—Vandetanib—thyroid cancer	0.000823	0.00319	CcSEcCtD
Dipyridamole—Eructation—Doxorubicin—thyroid cancer	0.000823	0.00319	CcSEcCtD
Dipyridamole—Rash—Vandetanib—thyroid cancer	0.000816	0.00316	CcSEcCtD
Dipyridamole—Dermatitis—Vandetanib—thyroid cancer	0.000816	0.00316	CcSEcCtD
Dipyridamole—Headache—Vandetanib—thyroid cancer	0.000811	0.00314	CcSEcCtD
Dipyridamole—Pulmonary oedema—Epirubicin—thyroid cancer	0.000805	0.00312	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000796	0.00308	CcSEcCtD
Dipyridamole—Hypertonia—Epirubicin—thyroid cancer	0.000793	0.00307	CcSEcCtD
Dipyridamole—Dyspnoea—Sorafenib—thyroid cancer	0.000779	0.00302	CcSEcCtD
Dipyridamole—Nausea—Vandetanib—thyroid cancer	0.000769	0.00298	CcSEcCtD
Dipyridamole—Dyspepsia—Sorafenib—thyroid cancer	0.000769	0.00298	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000754	0.00292	CcSEcCtD
Dipyridamole—Fatigue—Sorafenib—thyroid cancer	0.000753	0.00292	CcSEcCtD
Dipyridamole—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000752	0.00291	CcSEcCtD
Dipyridamole—Pain—Sorafenib—thyroid cancer	0.000747	0.00289	CcSEcCtD
Dipyridamole—Pulmonary oedema—Doxorubicin—thyroid cancer	0.000745	0.00289	CcSEcCtD
Dipyridamole—Hypertonia—Doxorubicin—thyroid cancer	0.000734	0.00284	CcSEcCtD
Dipyridamole—Eye pain—Epirubicin—thyroid cancer	0.000728	0.00282	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000714	0.00277	CcSEcCtD
Dipyridamole—Hot flush—Epirubicin—thyroid cancer	0.000702	0.00272	CcSEcCtD
Dipyridamole—Increased appetite—Epirubicin—thyroid cancer	0.000699	0.00271	CcSEcCtD
Dipyridamole—Menopausal symptoms—Epirubicin—thyroid cancer	0.000696	0.0027	CcSEcCtD
Dipyridamole—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000695	0.00269	CcSEcCtD
Dipyridamole—Urticaria—Sorafenib—thyroid cancer	0.000694	0.00269	CcSEcCtD
Dipyridamole—Abdominal pain—Sorafenib—thyroid cancer	0.000691	0.00267	CcSEcCtD
Dipyridamole—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000679	0.00263	CcSEcCtD
Dipyridamole—Eye pain—Doxorubicin—thyroid cancer	0.000673	0.00261	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00067	0.0026	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000657	0.00254	CcSEcCtD
Dipyridamole—Hot flush—Doxorubicin—thyroid cancer	0.00065	0.00252	CcSEcCtD
Dipyridamole—Increased appetite—Doxorubicin—thyroid cancer	0.000647	0.00251	CcSEcCtD
Dipyridamole—Migraine—Epirubicin—thyroid cancer	0.000647	0.0025	CcSEcCtD
Dipyridamole—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000644	0.00249	CcSEcCtD
Dipyridamole—Hypersensitivity—Sorafenib—thyroid cancer	0.000644	0.00249	CcSEcCtD
Dipyridamole—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000628	0.00243	CcSEcCtD
Dipyridamole—Asthenia—Sorafenib—thyroid cancer	0.000627	0.00243	CcSEcCtD
Dipyridamole—Cardiac arrest—Epirubicin—thyroid cancer	0.000625	0.00242	CcSEcCtD
Dipyridamole—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00062	0.0024	CcSEcCtD
Dipyridamole—Pruritus—Sorafenib—thyroid cancer	0.000618	0.00239	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000608	0.00235	CcSEcCtD
Dipyridamole—ABCB1—trachea—thyroid cancer	0.000602	0.00259	CbGeAlD
Dipyridamole—Orthostatic hypotension—Epirubicin—thyroid cancer	0.0006	0.00232	CcSEcCtD
Dipyridamole—Abdominal pain upper—Epirubicin—thyroid cancer	0.0006	0.00232	CcSEcCtD
Dipyridamole—Migraine—Doxorubicin—thyroid cancer	0.000598	0.00232	CcSEcCtD
Dipyridamole—Diarrhoea—Sorafenib—thyroid cancer	0.000598	0.00231	CcSEcCtD
Dipyridamole—Cardiac arrest—Doxorubicin—thyroid cancer	0.000578	0.00224	CcSEcCtD
Dipyridamole—Dizziness—Sorafenib—thyroid cancer	0.000578	0.00224	CcSEcCtD
Dipyridamole—Dysphagia—Epirubicin—thyroid cancer	0.000568	0.0022	CcSEcCtD
Dipyridamole—Vomiting—Sorafenib—thyroid cancer	0.000555	0.00215	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000555	0.00215	CcSEcCtD
Dipyridamole—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000555	0.00215	CcSEcCtD
Dipyridamole—Angina pectoris—Epirubicin—thyroid cancer	0.000553	0.00214	CcSEcCtD
Dipyridamole—Rash—Sorafenib—thyroid cancer	0.000551	0.00213	CcSEcCtD
Dipyridamole—Dermatitis—Sorafenib—thyroid cancer	0.00055	0.00213	CcSEcCtD
Dipyridamole—Headache—Sorafenib—thyroid cancer	0.000547	0.00212	CcSEcCtD
Dipyridamole—Dysphagia—Doxorubicin—thyroid cancer	0.000525	0.00203	CcSEcCtD
Dipyridamole—Nausea—Sorafenib—thyroid cancer	0.000519	0.00201	CcSEcCtD
Dipyridamole—Angina pectoris—Doxorubicin—thyroid cancer	0.000512	0.00198	CcSEcCtD
Dipyridamole—ABCB1—thyroid gland—thyroid cancer	0.000476	0.00205	CbGeAlD
Dipyridamole—Bradycardia—Epirubicin—thyroid cancer	0.000463	0.00179	CcSEcCtD
Dipyridamole—Haemoglobin—Epirubicin—thyroid cancer	0.000457	0.00177	CcSEcCtD
Dipyridamole—Rhinitis—Epirubicin—thyroid cancer	0.000456	0.00176	CcSEcCtD
Dipyridamole—Hepatitis—Epirubicin—thyroid cancer	0.000454	0.00176	CcSEcCtD
Dipyridamole—Haemorrhage—Epirubicin—thyroid cancer	0.000454	0.00176	CcSEcCtD
Dipyridamole—Hypoaesthesia—Epirubicin—thyroid cancer	0.000452	0.00175	CcSEcCtD
Dipyridamole—Pharyngitis—Epirubicin—thyroid cancer	0.000451	0.00175	CcSEcCtD
Dipyridamole—Bradycardia—Doxorubicin—thyroid cancer	0.000428	0.00166	CcSEcCtD
Dipyridamole—Tinnitus—Epirubicin—thyroid cancer	0.000424	0.00164	CcSEcCtD
Dipyridamole—Haemoglobin—Doxorubicin—thyroid cancer	0.000423	0.00164	CcSEcCtD
Dipyridamole—ABCB1—head—thyroid cancer	0.000422	0.00182	CbGeAlD
Dipyridamole—Flushing—Epirubicin—thyroid cancer	0.000422	0.00163	CcSEcCtD
Dipyridamole—Cardiac disorder—Epirubicin—thyroid cancer	0.000422	0.00163	CcSEcCtD
Dipyridamole—Rhinitis—Doxorubicin—thyroid cancer	0.000421	0.00163	CcSEcCtD
Dipyridamole—Haemorrhage—Doxorubicin—thyroid cancer	0.00042	0.00163	CcSEcCtD
Dipyridamole—Hepatitis—Doxorubicin—thyroid cancer	0.00042	0.00163	CcSEcCtD
Dipyridamole—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000418	0.00162	CcSEcCtD
Dipyridamole—Pharyngitis—Doxorubicin—thyroid cancer	0.000417	0.00162	CcSEcCtD
Dipyridamole—Angiopathy—Epirubicin—thyroid cancer	0.000412	0.0016	CcSEcCtD
Dipyridamole—Immune system disorder—Epirubicin—thyroid cancer	0.00041	0.00159	CcSEcCtD
Dipyridamole—Mediastinal disorder—Epirubicin—thyroid cancer	0.00041	0.00159	CcSEcCtD
Dipyridamole—Chills—Epirubicin—thyroid cancer	0.000408	0.00158	CcSEcCtD
Dipyridamole—Arrhythmia—Epirubicin—thyroid cancer	0.000406	0.00157	CcSEcCtD
Dipyridamole—Alopecia—Epirubicin—thyroid cancer	0.000402	0.00156	CcSEcCtD
Dipyridamole—Tinnitus—Doxorubicin—thyroid cancer	0.000392	0.00152	CcSEcCtD
Dipyridamole—Flushing—Doxorubicin—thyroid cancer	0.00039	0.00151	CcSEcCtD
Dipyridamole—Cardiac disorder—Doxorubicin—thyroid cancer	0.00039	0.00151	CcSEcCtD
Dipyridamole—Flatulence—Epirubicin—thyroid cancer	0.00039	0.00151	CcSEcCtD
Dipyridamole—Tension—Epirubicin—thyroid cancer	0.000388	0.0015	CcSEcCtD
Dipyridamole—Dysgeusia—Epirubicin—thyroid cancer	0.000387	0.0015	CcSEcCtD
Dipyridamole—Nervousness—Epirubicin—thyroid cancer	0.000384	0.00149	CcSEcCtD
Dipyridamole—Back pain—Epirubicin—thyroid cancer	0.000383	0.00148	CcSEcCtD
Dipyridamole—Angiopathy—Doxorubicin—thyroid cancer	0.000381	0.00148	CcSEcCtD
Dipyridamole—Muscle spasms—Epirubicin—thyroid cancer	0.00038	0.00147	CcSEcCtD
Dipyridamole—Immune system disorder—Doxorubicin—thyroid cancer	0.00038	0.00147	CcSEcCtD
Dipyridamole—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000379	0.00147	CcSEcCtD
Dipyridamole—Chills—Doxorubicin—thyroid cancer	0.000377	0.00146	CcSEcCtD
Dipyridamole—Arrhythmia—Doxorubicin—thyroid cancer	0.000376	0.00145	CcSEcCtD
Dipyridamole—Alopecia—Doxorubicin—thyroid cancer	0.000372	0.00144	CcSEcCtD
Dipyridamole—Ill-defined disorder—Epirubicin—thyroid cancer	0.000367	0.00142	CcSEcCtD
Dipyridamole—Anaemia—Epirubicin—thyroid cancer	0.000366	0.00142	CcSEcCtD
Dipyridamole—Flatulence—Doxorubicin—thyroid cancer	0.000361	0.0014	CcSEcCtD
Dipyridamole—Tension—Doxorubicin—thyroid cancer	0.000359	0.00139	CcSEcCtD
Dipyridamole—Dysgeusia—Doxorubicin—thyroid cancer	0.000358	0.00139	CcSEcCtD
Dipyridamole—Malaise—Epirubicin—thyroid cancer	0.000357	0.00138	CcSEcCtD
Dipyridamole—Nervousness—Doxorubicin—thyroid cancer	0.000355	0.00138	CcSEcCtD
Dipyridamole—Vertigo—Epirubicin—thyroid cancer	0.000355	0.00138	CcSEcCtD
Dipyridamole—Syncope—Epirubicin—thyroid cancer	0.000355	0.00137	CcSEcCtD
Dipyridamole—Back pain—Doxorubicin—thyroid cancer	0.000354	0.00137	CcSEcCtD
Dipyridamole—Muscle spasms—Doxorubicin—thyroid cancer	0.000352	0.00136	CcSEcCtD
Dipyridamole—Palpitations—Epirubicin—thyroid cancer	0.00035	0.00135	CcSEcCtD
Dipyridamole—Loss of consciousness—Epirubicin—thyroid cancer	0.000348	0.00135	CcSEcCtD
Dipyridamole—Cough—Epirubicin—thyroid cancer	0.000345	0.00134	CcSEcCtD
Dipyridamole—Convulsion—Epirubicin—thyroid cancer	0.000343	0.00133	CcSEcCtD
Dipyridamole—Hypertension—Epirubicin—thyroid cancer	0.000342	0.00132	CcSEcCtD
Dipyridamole—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00034	0.00132	CcSEcCtD
Dipyridamole—Anaemia—Doxorubicin—thyroid cancer	0.000338	0.00131	CcSEcCtD
Dipyridamole—Arthralgia—Epirubicin—thyroid cancer	0.000337	0.0013	CcSEcCtD
Dipyridamole—Chest pain—Epirubicin—thyroid cancer	0.000337	0.0013	CcSEcCtD
Dipyridamole—Myalgia—Epirubicin—thyroid cancer	0.000337	0.0013	CcSEcCtD
Dipyridamole—Anxiety—Epirubicin—thyroid cancer	0.000336	0.0013	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000334	0.0013	CcSEcCtD
Dipyridamole—Discomfort—Epirubicin—thyroid cancer	0.000333	0.00129	CcSEcCtD
Dipyridamole—Malaise—Doxorubicin—thyroid cancer	0.00033	0.00128	CcSEcCtD
Dipyridamole—Dry mouth—Epirubicin—thyroid cancer	0.000329	0.00128	CcSEcCtD
Dipyridamole—Vertigo—Doxorubicin—thyroid cancer	0.000329	0.00127	CcSEcCtD
Dipyridamole—Syncope—Doxorubicin—thyroid cancer	0.000328	0.00127	CcSEcCtD
Dipyridamole—Palpitations—Doxorubicin—thyroid cancer	0.000323	0.00125	CcSEcCtD
Dipyridamole—Anaphylactic shock—Epirubicin—thyroid cancer	0.000323	0.00125	CcSEcCtD
Dipyridamole—Oedema—Epirubicin—thyroid cancer	0.000323	0.00125	CcSEcCtD
Dipyridamole—Loss of consciousness—Doxorubicin—thyroid cancer	0.000322	0.00125	CcSEcCtD
Dipyridamole—Cough—Doxorubicin—thyroid cancer	0.000319	0.00124	CcSEcCtD
Dipyridamole—Shock—Epirubicin—thyroid cancer	0.000318	0.00123	CcSEcCtD
Dipyridamole—Convulsion—Doxorubicin—thyroid cancer	0.000317	0.00123	CcSEcCtD
Dipyridamole—Nervous system disorder—Epirubicin—thyroid cancer	0.000317	0.00123	CcSEcCtD
Dipyridamole—Thrombocytopenia—Epirubicin—thyroid cancer	0.000316	0.00122	CcSEcCtD
Dipyridamole—Hypertension—Doxorubicin—thyroid cancer	0.000316	0.00122	CcSEcCtD
Dipyridamole—Tachycardia—Epirubicin—thyroid cancer	0.000315	0.00122	CcSEcCtD
Dipyridamole—Skin disorder—Epirubicin—thyroid cancer	0.000314	0.00121	CcSEcCtD
Dipyridamole—Hyperhidrosis—Epirubicin—thyroid cancer	0.000312	0.00121	CcSEcCtD
Dipyridamole—Arthralgia—Doxorubicin—thyroid cancer	0.000312	0.00121	CcSEcCtD
Dipyridamole—Chest pain—Doxorubicin—thyroid cancer	0.000312	0.00121	CcSEcCtD
Dipyridamole—Myalgia—Doxorubicin—thyroid cancer	0.000312	0.00121	CcSEcCtD
Dipyridamole—Anxiety—Doxorubicin—thyroid cancer	0.000311	0.0012	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000309	0.0012	CcSEcCtD
Dipyridamole—Discomfort—Doxorubicin—thyroid cancer	0.000308	0.00119	CcSEcCtD
Dipyridamole—Dry mouth—Doxorubicin—thyroid cancer	0.000305	0.00118	CcSEcCtD
Dipyridamole—Hypotension—Epirubicin—thyroid cancer	0.000302	0.00117	CcSEcCtD
Dipyridamole—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000299	0.00116	CcSEcCtD
Dipyridamole—Oedema—Doxorubicin—thyroid cancer	0.000299	0.00116	CcSEcCtD
Dipyridamole—ABCB1—lymph node—thyroid cancer	0.000296	0.00128	CbGeAlD
Dipyridamole—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000294	0.00114	CcSEcCtD
Dipyridamole—Shock—Doxorubicin—thyroid cancer	0.000294	0.00114	CcSEcCtD
Dipyridamole—Nervous system disorder—Doxorubicin—thyroid cancer	0.000293	0.00113	CcSEcCtD
Dipyridamole—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000292	0.00113	CcSEcCtD
Dipyridamole—Tachycardia—Doxorubicin—thyroid cancer	0.000292	0.00113	CcSEcCtD
Dipyridamole—Skin disorder—Doxorubicin—thyroid cancer	0.00029	0.00112	CcSEcCtD
Dipyridamole—Paraesthesia—Epirubicin—thyroid cancer	0.00029	0.00112	CcSEcCtD
Dipyridamole—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000289	0.00112	CcSEcCtD
Dipyridamole—Dyspnoea—Epirubicin—thyroid cancer	0.000288	0.00111	CcSEcCtD
Dipyridamole—Somnolence—Epirubicin—thyroid cancer	0.000287	0.00111	CcSEcCtD
Dipyridamole—Dyspepsia—Epirubicin—thyroid cancer	0.000284	0.0011	CcSEcCtD
Dipyridamole—Hypotension—Doxorubicin—thyroid cancer	0.000279	0.00108	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000279	0.00108	CcSEcCtD
Dipyridamole—Fatigue—Epirubicin—thyroid cancer	0.000278	0.00108	CcSEcCtD
Dipyridamole—Pain—Epirubicin—thyroid cancer	0.000276	0.00107	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000272	0.00105	CcSEcCtD
Dipyridamole—Paraesthesia—Doxorubicin—thyroid cancer	0.000268	0.00104	CcSEcCtD
Dipyridamole—Dyspnoea—Doxorubicin—thyroid cancer	0.000266	0.00103	CcSEcCtD
Dipyridamole—Feeling abnormal—Epirubicin—thyroid cancer	0.000266	0.00103	CcSEcCtD
Dipyridamole—Somnolence—Doxorubicin—thyroid cancer	0.000266	0.00103	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000264	0.00102	CcSEcCtD
Dipyridamole—Dyspepsia—Doxorubicin—thyroid cancer	0.000263	0.00102	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000258	0.000999	CcSEcCtD
Dipyridamole—Fatigue—Doxorubicin—thyroid cancer	0.000258	0.000997	CcSEcCtD
Dipyridamole—Urticaria—Epirubicin—thyroid cancer	0.000256	0.000993	CcSEcCtD
Dipyridamole—Pain—Doxorubicin—thyroid cancer	0.000255	0.000989	CcSEcCtD
Dipyridamole—Abdominal pain—Epirubicin—thyroid cancer	0.000255	0.000988	CcSEcCtD
Dipyridamole—Feeling abnormal—Doxorubicin—thyroid cancer	0.000246	0.000953	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000244	0.000946	CcSEcCtD
Dipyridamole—Hypersensitivity—Epirubicin—thyroid cancer	0.000238	0.000921	CcSEcCtD
Dipyridamole—Urticaria—Doxorubicin—thyroid cancer	0.000237	0.000919	CcSEcCtD
Dipyridamole—Abdominal pain—Doxorubicin—thyroid cancer	0.000236	0.000915	CcSEcCtD
Dipyridamole—Asthenia—Epirubicin—thyroid cancer	0.000232	0.000897	CcSEcCtD
Dipyridamole—Pruritus—Epirubicin—thyroid cancer	0.000228	0.000885	CcSEcCtD
Dipyridamole—Diarrhoea—Epirubicin—thyroid cancer	0.000221	0.000855	CcSEcCtD
Dipyridamole—Hypersensitivity—Doxorubicin—thyroid cancer	0.00022	0.000852	CcSEcCtD
Dipyridamole—Asthenia—Doxorubicin—thyroid cancer	0.000214	0.00083	CcSEcCtD
Dipyridamole—Dizziness—Epirubicin—thyroid cancer	0.000213	0.000827	CcSEcCtD
Dipyridamole—Pruritus—Doxorubicin—thyroid cancer	0.000211	0.000819	CcSEcCtD
Dipyridamole—Vomiting—Epirubicin—thyroid cancer	0.000205	0.000795	CcSEcCtD
Dipyridamole—Diarrhoea—Doxorubicin—thyroid cancer	0.000204	0.000792	CcSEcCtD
Dipyridamole—Rash—Epirubicin—thyroid cancer	0.000204	0.000788	CcSEcCtD
Dipyridamole—Dermatitis—Epirubicin—thyroid cancer	0.000203	0.000788	CcSEcCtD
Dipyridamole—Headache—Epirubicin—thyroid cancer	0.000202	0.000783	CcSEcCtD
Dipyridamole—Dizziness—Doxorubicin—thyroid cancer	0.000198	0.000765	CcSEcCtD
Dipyridamole—Nausea—Epirubicin—thyroid cancer	0.000192	0.000743	CcSEcCtD
Dipyridamole—Vomiting—Doxorubicin—thyroid cancer	0.00019	0.000736	CcSEcCtD
Dipyridamole—Rash—Doxorubicin—thyroid cancer	0.000188	0.000729	CcSEcCtD
Dipyridamole—Dermatitis—Doxorubicin—thyroid cancer	0.000188	0.000729	CcSEcCtD
Dipyridamole—Headache—Doxorubicin—thyroid cancer	0.000187	0.000725	CcSEcCtD
Dipyridamole—Nausea—Doxorubicin—thyroid cancer	0.000177	0.000687	CcSEcCtD
Dipyridamole—PDE3B—Signaling Pathways—NRG1—thyroid cancer	4.74e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling by GPCR—AKT1—thyroid cancer	4.72e-05	0.000119	CbGpPWpGaD
Dipyridamole—ABCC4—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	4.64e-05	0.000117	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDK1—thyroid cancer	4.62e-05	0.000117	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—KRAS—thyroid cancer	4.6e-05	0.000116	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—CCND1—thyroid cancer	4.58e-05	0.000116	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—HRAS—thyroid cancer	4.57e-05	0.000115	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HIF1A—thyroid cancer	4.55e-05	0.000115	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—HRAS—thyroid cancer	4.54e-05	0.000115	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—HRAS—thyroid cancer	4.54e-05	0.000115	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—KRAS—thyroid cancer	4.53e-05	0.000114	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—KRAS—thyroid cancer	4.48e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—KRAS—thyroid cancer	4.48e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NRG1—thyroid cancer	4.43e-05	0.000112	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—NRAS—thyroid cancer	4.43e-05	0.000112	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—NRAS—thyroid cancer	4.43e-05	0.000112	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—PTEN—thyroid cancer	4.42e-05	0.000112	CbGpPWpGaD
Dipyridamole—PDE11A—GPCR downstream signaling—AKT1—thyroid cancer	4.42e-05	0.000112	CbGpPWpGaD
Dipyridamole—PDE7A—GPCR downstream signaling—AKT1—thyroid cancer	4.42e-05	0.000112	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—NRAS—thyroid cancer	4.4e-05	0.000111	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—TP53—thyroid cancer	4.35e-05	0.00011	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling by GPCR—AKT1—thyroid cancer	4.32e-05	0.000109	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—NRAS—thyroid cancer	4.32e-05	0.000109	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NRG1—thyroid cancer	4.31e-05	0.000109	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HPGD—thyroid cancer	4.27e-05	0.000108	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—CCND1—thyroid cancer	4.26e-05	0.000108	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—CCND1—thyroid cancer	4.26e-05	0.000108	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TERT—thyroid cancer	4.25e-05	0.000107	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—HRAS—thyroid cancer	4.21e-05	0.000106	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—KRAS—thyroid cancer	4.21e-05	0.000106	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—KRAS—thyroid cancer	4.18e-05	0.000106	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—HRAS—thyroid cancer	4.16e-05	0.000105	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—KRAS—thyroid cancer	4.14e-05	0.000105	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—KRAS—thyroid cancer	4.13e-05	0.000104	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—BRAF—thyroid cancer	4.12e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—BRAF—thyroid cancer	4.12e-05	0.000104	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	4.12e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—PTEN—thyroid cancer	4.11e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—PTEN—thyroid cancer	4.11e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—TP53—thyroid cancer	4.09e-05	0.000103	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HIF1A—thyroid cancer	4.07e-05	0.000103	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NRG1—thyroid cancer	4.06e-05	0.000102	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—HRAS—thyroid cancer	4.05e-05	0.000102	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—AKT1—thyroid cancer	4.03e-05	0.000102	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—AKT1—thyroid cancer	4.01e-05	0.000101	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—AKT1—thyroid cancer	4.01e-05	0.000101	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—TP53—thyroid cancer	3.98e-05	0.000101	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—TP53—thyroid cancer	3.98e-05	0.000101	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TERT—thyroid cancer	3.98e-05	0.0001	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—CCND1—thyroid cancer	3.95e-05	9.97e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—NRAS—thyroid cancer	3.95e-05	9.96e-05	CbGpPWpGaD
Dipyridamole—PDE10A—GPCR downstream signaling—AKT1—thyroid cancer	3.94e-05	9.94e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.92e-05	9.88e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—HRAS—thyroid cancer	3.91e-05	9.87e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—CCND1—thyroid cancer	3.9e-05	9.84e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TERT—thyroid cancer	3.87e-05	9.77e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—HRAS—thyroid cancer	3.85e-05	9.71e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PTGS2—thyroid cancer	3.83e-05	9.68e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—PTEN—thyroid cancer	3.81e-05	9.62e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—KRAS—thyroid cancer	3.81e-05	9.62e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—KRAS—thyroid cancer	3.81e-05	9.62e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—HRAS—thyroid cancer	3.81e-05	9.62e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—HRAS—thyroid cancer	3.81e-05	9.62e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HIF1A—thyroid cancer	3.81e-05	9.61e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—CCND1—thyroid cancer	3.8e-05	9.59e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—KRAS—thyroid cancer	3.79e-05	9.56e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—BRAF—thyroid cancer	3.77e-05	9.51e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—PTEN—thyroid cancer	3.76e-05	9.49e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—TP53—thyroid cancer	3.74e-05	9.44e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—AKT1—thyroid cancer	3.72e-05	9.39e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.72e-05	9.39e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—KRAS—thyroid cancer	3.71e-05	9.37e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NRG1—thyroid cancer	3.71e-05	9.36e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—NRAS—thyroid cancer	3.71e-05	9.35e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HIF1A—thyroid cancer	3.7e-05	9.35e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—AKT1—thyroid cancer	3.67e-05	9.27e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—NRAS—thyroid cancer	3.67e-05	9.26e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—NRAS—thyroid cancer	3.67e-05	9.26e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—PTEN—thyroid cancer	3.67e-05	9.25e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TERT—thyroid cancer	3.64e-05	9.19e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.59e-05	9.06e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—NRAS—thyroid cancer	3.58e-05	9.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—HRAS—thyroid cancer	3.58e-05	9.03e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—AKT1—thyroid cancer	3.58e-05	9.03e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—HRAS—thyroid cancer	3.55e-05	8.97e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PPARG—thyroid cancer	3.54e-05	8.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—HRAS—thyroid cancer	3.52e-05	8.89e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—HRAS—thyroid cancer	3.51e-05	8.85e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HIF1A—thyroid cancer	3.48e-05	8.79e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—AKT1—thyroid cancer	3.45e-05	8.71e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—NRAS—thyroid cancer	3.4e-05	8.59e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—AKT1—thyroid cancer	3.4e-05	8.58e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—KRAS—thyroid cancer	3.4e-05	8.57e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—TP53—thyroid cancer	3.39e-05	8.55e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—TP53—thyroid cancer	3.39e-05	8.55e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—BRAF—thyroid cancer	3.37e-05	8.5e-05	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—AKT1—thyroid cancer	3.36e-05	8.49e-05	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—AKT1—thyroid cancer	3.36e-05	8.49e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—NRAS—thyroid cancer	3.36e-05	8.47e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—NRAS—thyroid cancer	3.35e-05	8.47e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PTEN—thyroid cancer	3.34e-05	8.44e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TERT—thyroid cancer	3.33e-05	8.4e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTGS2—thyroid cancer	3.33e-05	8.39e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTGS2—thyroid cancer	3.33e-05	8.39e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—TP53—thyroid cancer	3.3e-05	8.33e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.29e-05	8.31e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—NRAS—thyroid cancer	3.27e-05	8.25e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—NRAS—thyroid cancer	3.26e-05	8.23e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—HRAS—thyroid cancer	3.24e-05	8.18e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—HRAS—thyroid cancer	3.24e-05	8.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—HRAS—thyroid cancer	3.22e-05	8.13e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—KRAS—thyroid cancer	3.19e-05	8.05e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HIF1A—thyroid cancer	3.19e-05	8.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—AKT1—thyroid cancer	3.16e-05	7.97e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—KRAS—thyroid cancer	3.16e-05	7.97e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—KRAS—thyroid cancer	3.16e-05	7.97e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—HRAS—thyroid cancer	3.16e-05	7.97e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—BRAF—thyroid cancer	3.15e-05	7.96e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PTEN—thyroid cancer	3.14e-05	7.93e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—AKT1—thyroid cancer	3.14e-05	7.92e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—AKT1—thyroid cancer	3.11e-05	7.85e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—AKT1—thyroid cancer	3.1e-05	7.81e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—KRAS—thyroid cancer	3.08e-05	7.78e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—NRAS—thyroid cancer	3.07e-05	7.74e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—BRAF—thyroid cancer	3.07e-05	7.74e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTGS2—thyroid cancer	3.04e-05	7.68e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—TP53—thyroid cancer	3.02e-05	7.62e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—KRAS—thyroid cancer	2.93e-05	7.39e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTEN—thyroid cancer	2.9e-05	7.32e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTEN—thyroid cancer	2.9e-05	7.32e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—KRAS—thyroid cancer	2.89e-05	7.29e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—HRAS—thyroid cancer	2.89e-05	7.29e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—KRAS—thyroid cancer	2.89e-05	7.29e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—BRAF—thyroid cancer	2.88e-05	7.28e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PTEN—thyroid cancer	2.87e-05	7.25e-05	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—AKT1—thyroid cancer	2.86e-05	7.22e-05	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—AKT1—thyroid cancer	2.86e-05	7.22e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—AKT1—thyroid cancer	2.84e-05	7.18e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—TP53—thyroid cancer	2.83e-05	7.15e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—KRAS—thyroid cancer	2.82e-05	7.1e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—KRAS—thyroid cancer	2.81e-05	7.09e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TP53—thyroid cancer	2.81e-05	7.08e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TP53—thyroid cancer	2.81e-05	7.08e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—NRAS—thyroid cancer	2.81e-05	7.08e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—NRAS—thyroid cancer	2.8e-05	7.07e-05	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—AKT1—thyroid cancer	2.79e-05	7.04e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTGS2—thyroid cancer	2.79e-05	7.03e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.76e-05	6.96e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—HRAS—thyroid cancer	2.71e-05	6.84e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—HRAS—thyroid cancer	2.68e-05	6.77e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—HRAS—thyroid cancer	2.68e-05	6.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTEN—thyroid cancer	2.65e-05	6.7e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—KRAS—thyroid cancer	2.64e-05	6.66e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—BRAF—thyroid cancer	2.64e-05	6.66e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—HRAS—thyroid cancer	2.62e-05	6.61e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TP53—thyroid cancer	2.6e-05	6.57e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—NRAS—thyroid cancer	2.59e-05	6.53e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—NRAS—thyroid cancer	2.59e-05	6.53e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—thyroid cancer	2.57e-05	6.48e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—NRAS—thyroid cancer	2.56e-05	6.47e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—AKT1—thyroid cancer	2.55e-05	6.43e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—AKT1—thyroid cancer	2.55e-05	6.43e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—thyroid cancer	2.5e-05	6.31e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—HRAS—thyroid cancer	2.49e-05	6.28e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—thyroid cancer	2.46e-05	6.2e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HRAS—thyroid cancer	2.46e-05	6.2e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—HRAS—thyroid cancer	2.45e-05	6.19e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—TPR—thyroid cancer	2.45e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.45e-05	6.18e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTEN—thyroid cancer	2.43e-05	6.13e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—thyroid cancer	2.42e-05	6.09e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—thyroid cancer	2.41e-05	6.09e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.41e-05	6.08e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—AKT1—thyroid cancer	2.39e-05	6.04e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HRAS—thyroid cancer	2.39e-05	6.04e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—HRAS—thyroid cancer	2.39e-05	6.02e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—AKT1—thyroid cancer	2.39e-05	6.02e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PTEN—thyroid cancer	2.37e-05	5.99e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—AKT1—thyroid cancer	2.37e-05	5.98e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—AKT1—thyroid cancer	2.37e-05	5.98e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NRAS—thyroid cancer	2.37e-05	5.97e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT1—thyroid cancer	2.32e-05	5.86e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT1—thyroid cancer	2.31e-05	5.84e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—thyroid cancer	2.3e-05	5.81e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—HRAS—thyroid cancer	2.24e-05	5.66e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—thyroid cancer	2.24e-05	5.65e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—thyroid cancer	2.23e-05	5.62e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—thyroid cancer	2.23e-05	5.62e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PTEN—thyroid cancer	2.22e-05	5.61e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—thyroid cancer	2.21e-05	5.57e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT1—thyroid cancer	2.2e-05	5.55e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT1—thyroid cancer	2.18e-05	5.51e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT1—thyroid cancer	2.17e-05	5.47e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT1—thyroid cancer	2.17e-05	5.47e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PTEN—thyroid cancer	2.16e-05	5.45e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NRAS—thyroid cancer	2.12e-05	5.34e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT1—thyroid cancer	2.11e-05	5.33e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT1—thyroid cancer	2.11e-05	5.32e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—thyroid cancer	2.1e-05	5.31e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.07e-05	5.22e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—HRAS—thyroid cancer	2.05e-05	5.18e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HRAS—thyroid cancer	2.05e-05	5.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—thyroid cancer	2.04e-05	5.14e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTEN—thyroid cancer	2.03e-05	5.13e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT1—thyroid cancer	2e-05	5.04e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT1—thyroid cancer	1.98e-05	5e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NRAS—thyroid cancer	1.98e-05	5e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NRAS—thyroid cancer	1.93e-05	4.86e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—AKT1—thyroid cancer	1.93e-05	4.86e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—thyroid cancer	1.93e-05	4.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—HRAS—thyroid cancer	1.89e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HRAS—thyroid cancer	1.89e-05	4.78e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HRAS—thyroid cancer	1.88e-05	4.73e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTEN—thyroid cancer	1.86e-05	4.69e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.83e-05	4.63e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—thyroid cancer	1.82e-05	4.6e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT1—thyroid cancer	1.81e-05	4.57e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NRAS—thyroid cancer	1.81e-05	4.57e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT1—thyroid cancer	1.81e-05	4.57e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HRAS—thyroid cancer	1.73e-05	4.37e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—thyroid cancer	1.71e-05	4.3e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT1—thyroid cancer	1.67e-05	4.22e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT1—thyroid cancer	1.67e-05	4.22e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—thyroid cancer	1.66e-05	4.19e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NRAS—thyroid cancer	1.66e-05	4.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT1—thyroid cancer	1.66e-05	4.18e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—thyroid cancer	1.62e-05	4.09e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—thyroid cancer	1.56e-05	3.94e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HRAS—thyroid cancer	1.55e-05	3.91e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—RXRA—thyroid cancer	1.54e-05	3.89e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT1—thyroid cancer	1.53e-05	3.86e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—thyroid cancer	1.52e-05	3.83e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—thyroid cancer	1.47e-05	3.72e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HRAS—thyroid cancer	1.45e-05	3.66e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—thyroid cancer	1.43e-05	3.6e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HRAS—thyroid cancer	1.41e-05	3.56e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—AKT1—thyroid cancer	1.4e-05	3.53e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—thyroid cancer	1.39e-05	3.5e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT1—thyroid cancer	1.37e-05	3.45e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HRAS—thyroid cancer	1.33e-05	3.35e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT1—thyroid cancer	1.28e-05	3.23e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—thyroid cancer	1.27e-05	3.2e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT1—thyroid cancer	1.25e-05	3.14e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HRAS—thyroid cancer	1.21e-05	3.06e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT1—thyroid cancer	1.17e-05	2.95e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT1—thyroid cancer	1.07e-05	2.7e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARG—thyroid cancer	9.73e-06	2.46e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—thyroid cancer	7.66e-06	1.93e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTEN—thyroid cancer	6.68e-06	1.68e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKT1—thyroid cancer	3.85e-06	9.71e-06	CbGpPWpGaD
